You need to enable JavaScript to run this app.
Recon: CMS to restrict coverage of Aduhelm to only clinical trials; FDA warns of dental issues with buprenorphine
Recon
Biologics
Biotechnology
Diagnostics
Global
Medical Devices
North America
Pharmaceuticals
Regulatory Intelligence/Policy